ArticleWorld journal of nephrology2026
Five-year follow-up sustained remission with rituximab in a patient with focal segmental glomerulosclerosis: A case report.
Article in World journal of nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFocal segmental glomerulosclerosis (FSGS) represents a major cause of nephrotic syndrome, with glucocorticoids constituting first-line therapy. When patients develop steroid dependence or resistance, calcineurin inhibitors (CNIs) serve as effective alternatives. However, CNI dependence or resistance may emerge, and prolonged use of either steroid or CNI therapy carries substantial toxicity risks. These limitations create an unmet need for safer treatments capable of maintaining durable remission. CASE SUMMARY: The patient initially presented with acute anasarca, nephrotic-range proteinuria (5.6 g/24 hours), hypoalbuminemia (2.1 g/dL), and preserved renal function. She experienced repeated relapses after corticosteroid and cyclosporine tapering, ultimately exhibiting a steroid- and CNI-dependent disease course. Rituximab was administered as two 1 g infusions 14 days apart, resulting in complete remission sustained for five years.
conclusionThis case contributes to the growing evidence supporting rituximab's therapeutic potential in adult FSGS, while highlighting the need for randomized controlled trials to establish its efficacy and optimal use in this challenging patient population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.